KRAS mutations code for abnormally activated Kras proteins that result in an autonomal activation of its downstream effectors. They account for 10%-30% of lung cancers (Table 1) , mainly in adenocarcinoma, and have been linked with smoking history. KRAS mutations have been associated with lack of responsiveness to anti-epidermal growth factor receptor (EGFR) antibodies in colorectal cancer. Consecutively, cetuximab and panitumumab are only delivered to wild-type KRAS colorectal cancer patients. However, the transposition of this pattern to patients with non-small-cell lung cancer (NSCLC) is highly debated. On the first hand, the results from all prospective studies yet presented (BR.21, SATURN, FLEX, BMS099, TRUST) failed to establish a clear relationship between KRAS status and efficacy of EGFR inhibitors. On the other hand, most of the NSCLC series report the lack of efficacy of EGFR inhibitors in case of KRAS mutation (Table 1) . Moreover, a recent meta-analysis conducted on 17 trials testing EGFR inhibitors in NSCLC [17] estimated that KRAS mutation could predict resistance to EGFR inhibitors (negative likelihood ratio = 0.84) (0.94; 95% CI 0.89-0.97).
Furthermore, the responses we describe here are also much longer than those habitually reported in the same situation for nonselected patients [20] . Our report highlights two facts: (i) the noncomplete reliance between mutant KRAS status and lack of efficacy to EGFR inhibitors in NSCLC and (ii) a small subset of NSCLC mutated for KRAS may exhibit long responses to EGFR inhibitors and possibly reflects a particular molecular circuit. Several hypotheses might explain these paradoxical responses. First of all, EGFR activation is not only mediated through KRAS signaling but also involves other pathways (PI3K/AKT/mTOR, phospholipase C, STAT, etc.). Tumors addicted to the latter ones could exhibit sensitive to EGFR inhibitors despite KRAS mutation. Furthermore, multiple Ras-guanosine triphosphatase proteins (i.e. p120GAP, neurofibromin) and negative feedback loops (i.e. Sprouty proteins as Spry-2, DUSSPs as DUSSP4, LKB1/TSC1-2) could downregulate Ras signaling even if exists a KRAS-activating mutation. Another proposition relies on the eventuality of concomitant molecular abnormalities that could activate EGFR. Few cases of coexistent EGFR mutation or EGFR amplification and KRAS mutations have been associated with increased sensitivity to EGFR inhibitors [21] . Such situation is, however, very unlikely since these abnormalities are mostly described as mutually exclusive from KRAS mutations. Another possible assumption is provided by recent results suggesting that cancer cell lines harboring KRAS mutations could be classified into KRAS-dependant and KRAS-independent groups. Only the former ones required KRAS mutation to maintain cell viability. A 'KRAS dependency' signature was developed and was even found to be strongly sensitive to EGFR inhibitors [22] . Finally, other theoretical hypotheses involving epigenetic variations, alternative splicing or posttranslational modifications could be involved in generating nonactive KRAS isoforms.
In summary, thoracic oncologists should be aware of the discrepancy between KRAS status and efficacy of EGFR inhibitors in NSCLC. A small subset of patients with KRAS mutations might paradoxically benefit from EGFR inhibitors. Clinical trials specially designed for this population are currently recruiting. Then, NSCLC patients with KRAS mutations should preferentially be included in these assays. 
